KUALA LUMPUR: Private equity investment company Goldis Bhd has reported a spike in its 3QFY12 results ended Oct 31 with net profit of RM237.41 million, up from RM11 million in the previous corresponding period mainly due to the disposal of assets.
Given the sharp jump in earnings, Goldis declared a second net interim dividend of 9.625 sen for FY12 ending Jan 31.
With 610.37 million shares issued, Goldis’ dividend payout should see roughly RM58.75 million in equity returned to its shareholders.
Proceeds from the disposal of Goldis subsidiary, HOEPharma Holdings Sdn Bhd to Taisho Pharmaceutical Co, which was completed on Aug 1, boosted 3Q earnings by RM221.23 million. Revenue rose nearly 50% to RM75.82 million from RM50.64 million previously.
Adjusting for the disposal of its subsidiary, which should be recorded as an extraordinary item, Goldis’ profits actually stand at RM16.18 million for 3Q, a 35.68% improvement from a year earlier.
Net assets per share jumped to RM2.32 from RM1.93, which can be attributed to the proceeds from the disposal of HOEPharma that boosted cash and bank balances to RM252.32 million as at Oct 31, compared with RM65.26 million at the same time last year. The sale of HOEPharma recorded RM275.32 million in Goldis’ cash flow statements.
Given the sharp jump in earnings, Goldis declared a second net interim dividend of 9.625 sen for FY12 ending Jan 31.
With 610.37 million shares issued, Goldis’ dividend payout should see roughly RM58.75 million in equity returned to its shareholders.
Proceeds from the disposal of Goldis subsidiary, HOEPharma Holdings Sdn Bhd to Taisho Pharmaceutical Co, which was completed on Aug 1, boosted 3Q earnings by RM221.23 million. Revenue rose nearly 50% to RM75.82 million from RM50.64 million previously.
Adjusting for the disposal of its subsidiary, which should be recorded as an extraordinary item, Goldis’ profits actually stand at RM16.18 million for 3Q, a 35.68% improvement from a year earlier.
Net assets per share jumped to RM2.32 from RM1.93, which can be attributed to the proceeds from the disposal of HOEPharma that boosted cash and bank balances to RM252.32 million as at Oct 31, compared with RM65.26 million at the same time last year. The sale of HOEPharma recorded RM275.32 million in Goldis’ cash flow statements.
